Neurizon Therapeutics Limited ABN 35 094 006 023 www.neurizon.com Suite 2, Level 11, 385 Bourke Street, Melbourne, VIC 3000 Tel: +61 3 9692 7222 Quarterly Report & Appendix 4C: Q4 FY26 Highlights: Clinical and preclinical development activity · HEALEY ALS...
Appendix 4C & Quarterly Update
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- Melbourne investor briefing presentation
- HEALEY ALS Platform Trial Regimen I enrolment completed - Topline results for NUZ-001 accelerated to Q2 CY2027
- HEALEY Enrolment Complete - Topline Accelerated to Q2 CY27
- Neurizon executes long-term supply agreement with Elanco
- HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule
Later from Neurizon Therapeutics
- Neurizon Enters Strategic R&D Financing Facility
- Neurizon Completes Initial Drawdown under R&D Facility
- Elanco representative appointed as Neurizon Board Observer
- Notification regarding unquoted securities - NUZ
- Appendix 4G and Corporate Governance Statement
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics